Abstract:Death Receptor 5 (DR5) targeted therapies offer significant promise due to their pivotal role in mediating the extrinsic pathway of apoptosis. Despite DR5 overexpression in various malignancies and the potential of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), clinical applications of anti-DR5 monoclonal antibodies (mAbs) have been hampered by suboptimal outcomes potentially due to lack of receptor clustering.To address the limitation, we developed N -(2-hydroxypropyl)methacrylamide (HPMA) copolymer-based conjugates integrating multiple copies of DR5-targeting peptide (cyclic WD C LDNRIGRRQ C VKL; cDR5) to enhance receptor clustering and apoptosis. Three conjugates with variable number of cDR5 were prepared and denoted as P H -cDR5 (high valence), P M -cDR5 (medium valence) and P L -cDR5 (low valence). Our studies in TRAIL-sensitive and resistant cancer cell lines demonstrated that the HPMA copolymer-peptide conjugates (P-cDR5) significantly improved DR5 receptor clustering and induced apoptosis effectively. In TRAIL-sensitive colon cancer cells (COLO205, HCT-116), P-cDR5 showed efficacy comparable to anti-DR5 mAb Drozitumab (DRO), but P-cDR5 outperformed DRO in TRAIL-resistant cells (HT-29), highlighting the importance of efficient receptor clustering. In COLO205 cells P M -cDR5 exhibited an IC50 of 94 pM, while P H -cDR5 had an even lower IC50 of 15 pM (based on cDR5 equivalent concentration), indicating enhanced potency of the multivalent HPMA copolymer-based system with a flexible polymer backbone in comparison with the IC 50 for TRAIL at 0.12 nM. Combining P-cDR5 with valproic acid, a histone deacetylase inhibitor, resulted in further enhancement of apoptosis inducing efficacy, along with destabilizing mitochondrial membranes and increased sensitivity of TRAIL-resistant cells. These findings suggest that attaching multiple cDR5 peptides to a flexible water-soluble polymer carrier not only overcomes the limitations of previous designs but also offers a promising avenue for treating resistant cancers, pointing toward the need for further preclinical exploration and validation of this innovative strategy.

Tumor-cell Specific Cytotoxic Activity of LBY135, a Novel Anti- DR5 Agonistic Antibody

Antitumor Efficacy of LBY135, an Anti-Dr5 Monoclonal Antibody, Alone or in Combination with Chemotherapy in Human Colon Tumor Cell Lines and Xenografts

Characterization of a Novel Anti-DR5 Monoclonal Antibody WD1 with the Potential to Induce Tumor Cell Apoptosis

A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity in Vitro and in Vivo

Structural Basis of LaDR5, a Novel Agonistic Anti-Death Receptor 5 (DR5) Monoclonal Antibody, to Inhibit DR5/TRAIL Complex Formation

The Characteristic of an Anti-Human DR5 Antibody A6

The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells.

Small-molecule Activation of the TRAIL Receptor DR5 in Human Cancer Cells

The Construction and Expression of A Novel Chimeric Anti-Dr5 Antibody

Analysis of aDR5scFv with Specific Identification and Function.

Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.

Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells

Induction of Apoptosis in U343 Cell Line by a Novel Anti-Human DR5 Monoclonal Antibody

[Construction and expression of anti-tumor necrosis factor related apoptosis-inducing ligand receptor death receptor 5 chimeric antibody in eukaryotic cells]

Analysis of Trail Receptor Expression Using Anti-Trail Death Receptor-5 Monoclonal Antibodies

Preparation and Characterization of A Set of Monoclonal Antibodies to Trail and Trail Receptors Dr4, Dr5, Dcr1, and Dcr2

Tumor-Derived Mutations in the Trail Receptor Dr5 Inhibit Trail Signaling Through the Dr4 Receptor by Competing for Ligand Binding

The Preparation and Tumor Cell Apoptosis-Inducing Activity Assay of Anti-Human DR5 Single-Chain Antibody

Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer

Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy

Novel immunotherapeutics against LGR5 to target multiple cancer types